Market Cap (In USD)
265.23 Million
Revenue (In USD)
12.59 Million
Net Income (In USD)
-112.64 Million
Avg. Volume
505.68 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 7.125-18.75
- PE
- -
- EPS
- -
- Beta Value
- 1.39
- ISIN
- US46565G1040
- CUSIP
- 46565G104
- CIK
- 1808865
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Michel Detheux Ph.D.
- Employee Count
- -
- Website
- https://www.iteostherapeutics.com
- Ipo Date
- 2020-07-24
- Details
- Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
More Stocks
-
CRR-UN
-
FRLOF
-
SHL
-
CIRXCirTran Corporation
CIRX
-
ORBTEXPOrbit Exports Limited
ORBTEXP
-
3DA
-
AGY
-
UTRX